CVS vs NVS
CVS Health vs Novartis AG — AI-powered side-by-side comparison
| Metric | CVS | NVS |
|---|
| AI Score |
53
|
72
|
| Price |
$93.05
|
$158.07
|
| P/E Ratio |
24.29×
|
24.02×
|
| ROE |
2.4%
|
30.5%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
14.2%
|
74.3%
|
| Debt / Equity |
0.96×
|
1.18×
|
| Dividend Yield |
2.9%
|
2.9%
|
| RSI (14) |
30.0
|
61.1
|
| Beta |
0.596
|
0.462
|
| Expected Upside |
+3.8%
|
+1.0%
|
AI Committee View
Current Innellis committee reasoning for CVS versus NVS.
NVS leads by 19 points.
NVS scores 72/100 (Buy) versus CVS at 53/100 (Watch).
CVS Committee View
50% agreement
6 analysts
The committee is genuinely divided. Macro Analyst sees a compelling case. Risk Analyst remains cautious — current ratio of 0.84 is tight -- limited short-term liquidity cushion. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Price-to-book of 1.3x is a discount to asset value — Value
- Dividend yield of 3.5% pays you to wait — Value
- 5 consecutive earnings beats -- consistent execution — Growth
Bear Case
- P/E of 25.0 is moderate-to-rich — Value
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
- MACD histogram negative -- bearish momentum — Technical
NVS Committee View
100% agreement
4 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- Risk/reward is unfavorable: 8.5% downside vs 1.0% upside.